Grand Rounds are interactive global webcasts delivered by industry-leading experts on a wide range of relevant topics. Listen to Drs. Bavaria and Klautz discuss Today's SAVR Patient: Case Based Discussions Valve Design and Impact on Clinical Outcomes.
Advancing ECLS therapy, this catheter is designed to optimize your patient's blood flow.
Care and caution should be taken to avoid damage to vessels and cardiac tissue during cannulation or other cardiac surgery procedures.
A design platform for long-term durability. Interior-mounted leaflets that leverage our proprietary AOA™ tissue treatment.
No clinical data is available which evaluates the long-term impact of AOA treatment in patients.
A complete portfolio of rigid, semi-rigid, and flexible annuloplasty products designed specifically for a more physiological mitral and tricuspid valve repair.See Our Options
™*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Crescent™* jugular dual lumen catheter is manufactured by MC3, Inc. and exclusively distributed by Medtronic. Crescent jugular dual lumen catheters are not approved in every geography.
Tadokoro N, Fukushima S, Shimahara Y, et al. Comparison of safety and haemodynamic performance between the Avalus™ stented aortic valve bioprosthesis and Magna™ valve in Japanese patients. Gen Thorac Cardiovasc Surg. July 2021;69(7):1060-1069.
The latest results of the Perigon Study, presented by Prof. Dr. Robert J.M. Klautz during EACTS 2020. The PERIGON Pivotal Trial regarding the Avalus valve is a prospective, interventional, nonrandomized, worldwide, multi-site trial, with each center following a common protocol. The study was designed in accordance with the recommendations of the EN ISO 5840:2009 standard for cardiac valve prostheses and the U.S. Food and Drug Administration (FDA) Heart Valve Guidance (2010; DRAFT) and conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Valve-related events and deaths were adjudicated by an independent clinical events committee (CEC). All study echocardiograms were analyzed by an independent core laboratory (MedStar Health Research Institute, Washington, D.C.). Safety oversight was provided by an independent data and safety monitoring board (DSMB). This trial is registered at www.clinicaltrials.gov, NCT02088554.